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ABSTRACT
Alternative promoters that are differentially used in
various cellular contexts and tissue types add to the
transcriptional complexity in mammalian genome.
Identificationofalternativepromotersandtheannota-
tion of their activity in different tissues is one of the
majorchallengesinunderstandingthetranscriptional
regulationofthemammaliangenesandtheirisoforms.
Todeterminetheuseofalternativepromotersindiffer-
ent tissues, we performed ChIP-seq experiments
usingantibodyagainstRNAPol-II,infiveadultmouse
tissues (brain, liver, lung, spleen and kidney). Our
analysis identified 38639 Pol-II promoters, including
12270 novel promoters, for both protein coding and
non-coding mouse genes. Of these, 6384 promoters
are tissue specific which are CpG poor and we find
that only 34% of the novel promoters are located in
CpG-rich regions, suggesting that novel promoters
are mostly tissue specific. By identifying the Pol-II
bound promoter(s) of each annotated gene in a given
tissue,wefoundthat37%oftheproteincodinggenes
use alternative promoters in the five mouse tissues.
The promoter annotations and ChIP-seq data pre-
sented here will aid ongoing efforts of characterizing
generegulatoryregionsinmammaliangenomes.
INTRODUCTION
Recent analyses of mammalian genomes and microarray
data suggest that the majority of mammalian genes
generate multiple transcripts and protein isoforms with
distinct functional roles. This transcript diversity is
generated, in part, through the use of alternative pro-
moters (1) and alternative splicing (2), which produce
pre-mRNA and mRNA isoforms respectively. The use
of alternative promoters plays a fundamental role in
regulating different gene isoforms, e.g. LEF1, TP73,
RUNX1 and MYC in various mammalian tissues and at
different developmental stages. For example, in case of
LEF1, the protein isoforms generated from the two pro-
moters perform opposing biological functions. While the
full-length LEF1, transcribed from upstream promoter,
interacts with b-catenin and regulates Wnt target genes,
the shorter isoform is incapable of binding b-catenin and
suppresses the regulation of Wnt targets through b-catenin
(3). Moreover, activation of upstream promoter and
silencing of the internal promoter is observed in most
colon cancers (4). Therefore, identifying primary and al-
ternative gene promoters in various normal tissues is
critical to understanding a diversity of physiological
processes associated with normal and diseased states in
different tissues. The advent of high-throughput molecular
technologies and computational methods to support this
technology has signiﬁcantly improved our ability to
annotate mammalian gene regulatory regions.
High-throughput technologies, such as cap analysis gene
expression (CAGE); chromatin immunoprecipitation
(ChIP) followed by microarray analysis (ChIP–chip);
ChIP coupled with pair-end ditag sequencing analysis
(ChIP-PET) (5,6); and, more recently, ChIP coupled
with sequencing (ChIP-seq) (7) are enabling the
genome-wide identiﬁcation of alternative promoters and
their patterns of use. This information will help us to
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variety of cell/tissue types, different developmental
stages and their misuse in disease conditions.
Growing evidence suggests that about half of the mam-
malian genes have multiple alternative promoters that can
span up to thousands of bases (8–12). For example, a
comprehensive analyses of 1% of the human genome in
16 diverse human cell lines, using transient transfection
reporter assays demonstrated the presence of functional
alternative promoters in >20% of genes (12). Similarly,
it has been reported that 35% of 100 human erythroid
genes examined have alternative promoters and that
24% of active genes in human ﬁbroblast cells possess
multiple promoters (13). This is quite a high percentage
of genes showing multiple promoter usage in a single bio-
logical process or cell type suggesting extensive use of
multiple promoters by mammalian genes. The knowledge
of alternative promoter usage in different mammalian
tissues is very limited and cannot be addressed without
high-resolution genome-wide mapping of the promoter
regions. However, the high-throughput approaches, such
as CAGE (14), deepCAGE (15), ChIP–chip (16,17) or
ChIP-seq (7), to annotate promoters at genome level
need to be applied with caution because of the inherent
problems with each method. For example, cytoplasmic
enzyme complexes can add caps to 50-monophosphate
RNA molecules generated by ribonuclease cleavage (18),
and hence CAGE tags could represent 50 ends of RNAs
generated by cleavage and subsequent re-capping (19).
CAGE analysis can also capture some non-capped tran-
scripts that may represent cleaved decaying mRNA (20).
Furthermore, a large number of CAGE tags are
distributed throughout the gene transcripts rendering it
inefﬁcient as a sole source of promoter identiﬁer.
Previously, we (16) and others (17) have performed
ChIP–chip analyses to identify the activity of mammalian
promoters across different cell and tissue types. However,
ChIP–chip requires design of genome-wide microarray to
probe the ChIP-bound DNA sequences. Additionally,
with either ChIP-chip or ChIP-seq technology promoters
cannot be identiﬁed solely on the presence of Pol-II en-
richment on a genomic location because of its enrichment
throughout the transcribed genomic region and lack of
highly speciﬁc antibodies that can distinguish promoter
bound Pol-II from elongating Pol-II. In order to
overcome these limitations of previous studies, we
pursued a combined Pol-II ChIP-seq and bioinformatics
promoter prediction approach to identify promoter
regions and their activity in ﬁve different mouse tissues.
We provide a genome-wide catalog of active promoters in
ﬁve tissues of adult mouse along with tissue-speciﬁc pro-
moters that will help future studies of transcriptional regu-
lation in mammalian genomes.
MATERIALS AND METHODS
Chromatin immunoprecipitation, massive parallel
sequencing and real-time polymerase chain reaction
About 1g of freshly dissected brain, kidney, liver, lung or
spleen tissue from 2-month-old FBV mice was minced
ﬁnely and cross-linked with 1% formaldehyde for 10min
at room temperature. To stop cross-linking, glycine was
added to a ﬁnal concentration of 0.125M. Next, the tissue
sample was treated to isolate individual cells and
cross-linked chromatin was fragmented to a size range
of 0.2–0.8kb as previously described (21). ChIP was per-
formed using 10mg of Pol-II antibody bound Dynal
magnetic beads. The antibodies against Pol-II were
purchased from Abcam Inc (ab5408) and Santa Cruz
Biotechnology (sc-899X). Following immunopre-
cipitation, the bound nucleoprotein complexes were exten-
sively washed six times with wash buffer 1 and once with
wash buffer 2 [Wash buffer 1: 50mM HEPES-KOH
(pH 7.55), 500mM LiCl, 1mM EDTA, 1.0% NP-40 and
0.7% Na-deoxycholate; wash buffer 2: TE containing
50mM NaCl] and the ChIP enriched DNA was eluted
and puriﬁed by phenol:chloroform:isoamyl alcohol extrac-
tion. This puriﬁed DNA (10ng) was further processed ac-
cording to the Illumina Inc. instructions to prepare the
library for sequencing ChIP enriched DNA. For
ChIP-qPCR, Pol-II ChIP was conducted the same way
as described above and same amount of either input or
Pol-II enriched DNA was PCR ampliﬁed in the presence
of speciﬁc primers using the SYBR green-based detection
(Applied Biosystems, Foster City, CA, USA) as described
previously (22). The primers used were as follows:
Promoter forward: 50 gacggttggagaagaaggtg 30, Promoter
reverse: 50 aggagaggaggaggttttgg 30 and Control region
forward: 50 gtaacctctgccgttcagga 30, Control region
reverse: 50 tttctccctttccggagatt 30.
ChIP-seq data processing
We have adapted a similar approach used by previous
published studies (7,23) for ChIP-seq data analysis.
Brieﬂy, the analysis involves the following steps: (i)
Identiﬁcation of statistically signiﬁcant sequence
read-enriched genomic regions (of length 1kb). A region
will be considered statistically signiﬁcant if the number of
reads within that region is higher than the number
expected due to random background. We used Poisson
distribution to estimate the background read count at a
given signiﬁcant level P (P 0.01). (ii) Creating the read
overlapping proﬁle for each identiﬁed region from step 1,
by extending the sequence reads from the 50 end to the 30
end of the reads up to 400bp (the average length of the
ChIP–DNA fragment sequenced from the Solexa GA with
Illumina standard ChIP-seq protocol). (iii) Peak identiﬁ-
cation—by counting the number of overlapped reads at
each nucleotide position and deﬁning the genomic
position with the highest number as the peak position
within the 1kb signiﬁcant region.
Identiﬁcation and annotation of Pol-II promoter peaks
To identify the Pol-II bound promoters from the ChIP-seq
data we used our recently developed program to discrim-
inate Pol-II enrichment peak associated with promoter
region from peaks associated with non-promoter region
(24). The method uses DNA sequence composition,
physico-chemical-structural property of DNA sequences,
CAGE tags, Pol-II and H3K4me3 enrichment proﬁles
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total, 39 features were calculated for each peak and as
described in ref. 24. Classiﬁcation model using the afore-
mentioned features was constructed with three different
state-of-the-art ensemble and meta classiﬁers: Random
forest (25), Bagging (26) and LogitBoost (27–30). The per-
formance of the model was evaluated based on the
promoter prediction metrics suggested by (31): sensitivity
(SN), positive predictive value (PPV), correlation coefﬁ-
cient (CC) and true-positive cost (TPC). The performance
measures were calculated for 10-fold cross-validation and
independent test set.
For annotating the predicted promoters, we referred to
gene information tracks from various sources available at
UCSC genome browser. The tracks include protein coding
and non-coding genes from Refseq gene, UCSC gene,
Ensembl gene, Vega gene and miRNA. We also down-
loaded recently discovered large intervening non-coding
RNAs (lincRNA) (32) information for annotating pro-
moters related to non-coding genes. The other non-coding
RNAs gene information including snoRNA and snRNA
are part of the Refseq gene, UCSC gene, Ensembl gene
and Vega gene models. A non-redundant set of coding and
non-coding transcripts was generated after combing the
transcript information from various gene models stated
above. A total of 42924 and 38159 coding and
non-coding transcripts, respectively, were obtained for an-
notation of Pol-II peaks (Supplementary Table S1A in
additional data ﬁle 2). The known protein-coding and
non-coding genes for organism other than mouse were
also considered for annotation. This was done to
identify those promoters that are evolutionarily conserved
and are known in other organisms but still unknown in
mouse. The non-mouse gene track was also downloaded
from UCSC genome browser and is referred as XenoRef
Gene. A non-redundant set of promoters for XenoRef
Gene track genes (Supplementary Table S1B in additional
data ﬁle 2) was also generated for annotation.
We divided the result of promoter annotation into three
categories: (i) known promoters, (ii) novel promoters and
(iii) novel promoters-unassigned. All those promoters that
overlapped with ﬁrst exon of known mouse transcripts are
categorized as ‘known promoters’. The rest of the pro-
moters are categorized as ‘novel promoters’. Further, the
novel promoters are assigned to known genes if those fall
inside a transcript of known mouse genes (or orthologous
non-mouse genes) or within  10kb of the 50end of known
mouse genes (or orthologous non-mouse genes). The rest
of the novel promoters are left as ‘Novel promoters –un-
assigned’. Those promoter peaks that overlap with the
50ends of both protein coding and non-coding genes are
assigned to both.
Cloning novel promoters and luciferase assay
PCR on mouse genomic DNA was performed with speciﬁc
primers to amplify 0.5–1.0kb of the randomly selected
novel promoter (0.5–1.0kb) and non-promoter
( 0.9kb) regions. The genomic coordinates of each
cloned promoter/non-promoter region is provided in
Supplementary Table S2. As a positive control for the
luciferase assay, the promoter of DLL1 gene was also
ampliﬁed. Ampliﬁed PCR products were cloned in pCRII
vector (Invitrogen) and the clones were conﬁrmed by
sequencing. The conﬁrmed clones were subcloned in the
promoter less luciferase vector pGL3basic (Promega
Inc.). DNA for the pGL3 basic constructs (1.8mg for
calcium chloride method, 0.9mg for Lipofectamine 2000
or Fugene) along with pGL4-renilla-luciferase (0.2mg for
calcium chloride method, 0.1mg for Lipofectamine 2000 or
Fugene) were individually transfected in HEK293 (calcium
chloride-basedtransfection),A549,HepG2(Lipofectamine
2000, Invitrogen Inc.), NIH3T3 and DAOY (Fugene,
Roche Inc.) cell lines in triplicates in six-well plate for
about 48h. After 48h, cells were washed and lyzed in
200ml of passive lysis buffer provided in the dual luciferase
assay kit (Promega Inc.). The lysates were cleared by cen-
trifugation andluciferase assaywas performed with 5–20ml
of the lysate as per manufacturer’s instructions (Promega
Inc.). Renilla luciferase activity was used to normalize for
transfection efﬁciencies and fold enrichment of luciferase
activity was calculated relative to the vector backbone
(pGL3 basic alone).
Core promoter identiﬁcation and analysis
We searched for core-promoter elements for each
identiﬁed promoter, by scanning a sequence of length
200bp (–100 to +100 around the Pol-II peak position).
The sequences were analyzed by MATCH program (33)
for the ﬁve known core-promoter elements (INR, TATA,
MTE, BRE and DPE) using the position weight matrices
published earlier (34). We used the default parameters for
the MATCH search with the following cutoffs for each
element (INR-0.85 and 0.8; TATA-0.73 and 0.58;
MTE-0.79 and 0.53; BRE-0.70 and 0.65; DPE-0.92 and
0.92). In this process, search was done ﬁrst for the INR
element because it is the most abundant core promoter
element, and if found, that position plus 3 was considered
as the true TSS for the corresponding promoter. If INR
was not found, the rest of the elements (TATA, MTE,
BRE and DPE) were searched in that order of importance,
and then the TSS was assigned relative to the ﬁrst element
found, by adjusting the relative distance between the TSS
and the corresponding element (34). The next priority was
given to TATA because though MTE is the second most
abundant core promoter element it shows high
co-occurrence with INR and the co-occurrence tendencies
of TATA element with others is least. If there are more
than one element identiﬁed in a sequence, priority is given
to the one with highest score. Once this assignment is
done, we looked for the presence of the remaining core
promoter elements in that promoter. If none of the
elements were present, the original peak position was
considered as the true TSS.
RESULTS
Pol-II ChIP-sequencing data quality
To identify the active promoter regions in the adult mouse
genome, we used the ChIP-seq approach to ﬁnd
genome-wide binding regions of Pol-II in ﬁve mouse
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mappingofthePol-IIbindingregions,weseektoinvestigate
the usage of alternative promoters and uncover novel pro-
moters in the mouse genome. Previous studies have
indicated that performing two biological replicates for
ChIP-seq studies is enough to achieve the sequencing
depth required for robust identiﬁcation of target binding
sites (35,36), and hence we performed two replicates of
Pol-II ChIP-seq experiment on each tissue and analyzed
their overlap. Following the ENCODE consortium stand-
ards (36), we analyzed the agreement between our two bio-
logical replicates and since our results indicate a good
correlation we combined the two datasets for further
analysis (Supplementary Figure S1 in additional data
ﬁle 1). Sequencing of Pol-II enriched DNA from two bio-
logicalreplicatesintheﬁvetissuesyieldedatotalofover102
million sequence reads of 36bp length. Using the ELAND
(Illumina, Inc., San Diego, CA, USA) and Bowtie (37)
programs and allowing a maximum of two mis-matches,
 62% (63.2 million) of the reads were uniquely mapped
back to the mouse reference genome (version mm9). The
aligned reads were processed to identify signiﬁcantly
enriched Pol-II binding regions and signiﬁcant peaks as
described in ‘Materials and Methods’ section. Following a
three-phase peak identiﬁcation approach, we identiﬁed a
total of 335468 signiﬁcantly Pol-II-enriched peaks across
the ﬁve tissues with brain showing the maximum number
ofpeaksfollowedbykidney,lung,liverandspleen(Table1).
As Pol-II binding is expected to be highly enriched in
promoter regions compared to intragenic locations, we
looked at the enrichment proﬁle of reads relative to
known transcription start sites (TSS). The distribution of
read counts per million mapped reads for each tissue indi-
cates an increased enrichment of Pol-II near TSS as
compared to intra and inter-genic regions (Figure 1A).
To further verify the quality of the ChIP-seq experimental
data, we performed ChIP-qPCR experiment on the ubiqui-
tous Polr2a locus. We analyzed the enrichment of Pol-II at
the promoter region as well as at a downstream region of
Polr2a gene as indicated in Figure 1B. Consistent with our
ChIP-seq data, we observed signiﬁcant Pol-II enrichment
only at the promoter region (Figure 1B and C).
Identiﬁcation and annotation of active promoters in the
mouse tissues
The major challenge in identifying promoters based on
Pol-II enriched regions/peaks is the presence of the
Figure 1. Pol-II ChIP-seq data quality. (A) Plot to show the distribu-
tion of ChIP-seq reads as normalized read counts per million around
known transcription start site (TSS) of known genes in the ﬁve tissues.
High Pol-II enrichment is observed around known TSS.
(B) Real-time-PCR results show the enrichment of Polr2a promoter
in Pol-II ChIP-enriched DNA from ﬁve mouse tissues (brain,
lung, liver, spleen and kidney). The primers (sequences provided
in the ‘Materials and Methods’ section) used in this ChIP-PCR
cover both the promoter region of Polr2a and the downstream
control region. The promoter region of Polr2a gene shows high
recruitment of Pol-II while no signiﬁcant enrichment is observed
in downstream Polr2a region. (C) Enrichment of ChIP-seq reads
around Polr2a sgene. The black box under the wiggle proﬁle
shows the position of the predicted promoters and the line
below identiﬁes the peaks that are statistically signiﬁcant. The y-axis
represents the normalized read counts per million mapped reads.
All ﬁve tissues show huge enrichment of read around promoter
region of Polr2a gene. The enrichment proﬁle is low inside gene for
all tissues.
Table 1. Summary of Pol II Chip-seq data processing for ﬁve tissues
Number of Brain Kidney Liver Lung Spleen
Read obtained from Solexa sequencer 17959062 20512406 24955539 17662905 21081878
Read aligned back to mouse genome (mm9) 10292266 13786546 14964945 10846984 13283139
Read in identiﬁed enriched region 5482173 6744056 6823960 5309423 5424148
Peaks identiﬁed 91712 81375 57816 72971 31594
Peaks predicted as promoters 18900 17548 14145 19415 10589
After alignment to the mouse genome, the enriched regions were ﬁrst identiﬁed and, using a statistical cutoff, the signiﬁcantly enriched peaks were
determined. The promoter prediction algorithm identiﬁed the signiﬁcantly enriched peaks that reside in promoter regions.
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result, all genomic regions bound by Pol-II are enriched
in the ChIP-seq experiments, producing signiﬁcantly large
number of enriched peaks after the initial statistical
analysis. This is clear from the cumulative distribution
of Pol-II peaks around known TSS, which indicates
that a signiﬁcant percentage of Pol-II bound loci are
also present outside known TSS/promoter regions
(Figure 2A). We have recently developed a computational
method that discriminates the Pol-II bound promoter
regions from Pol-II associations at non-promoter regions
(24). Moreover, in our study, we do not use an IgG
control as we have determined that our promoter identi-
ﬁcation analysis is not inﬂuenced by the use of IgG back-
ground subtraction (Supplementary Table S3 in additional
data ﬁle 2). We have performed promoter prediction on
Pol-II-enriched DNA from liver tissue with and without
the subtraction of IgG bound DNA background of liver
tissue. As shown in Supplementary Table S3, there is no
major change upon inclusion of IgG control but rather we
achieve slightly better results without background subtrac-
tion in terms of the number of promoters identiﬁed and
the overlap of identiﬁed promoters with the known ﬁrst
exons from various databases. Using this program, we
predicted  24% (80597) of the signiﬁcant Pol-II peaks
from the ﬁve tissues as promoter associated. As shown
in Figure 2B,  20–26% of the Pol-II peaks in brain,
kidney, liver and lung are in promoter regions and in
spleen almost 34% peaks correspond to promoters.
Further analysis suggested that nearly 85% of the
non-promoter Pol-II bound peaks were localized in
intragenic regions in liver and kidney compared to about
71% of non-promoter-enriched peaks in spleen intragenic
locations. Next, we compared the coverage of Pol-II en-
richment in the entire transcript with the sequence enrich-
ment at the corresponding promoter (Supplementary
Figure S2 in additional data ﬁle 1). For  5–7.5% of the
promoters in these ﬁve adult tissues, we found 4-fold or
more enrichment of the read around the promoter region
than the rest of the corresponding transcript, and we
speculate that these represent the paused promoters in
the adult tissues (38).
We analyzed the CpG richness of promoter and
non-promoter peaks based on the previously deﬁned
criteria (39). As expected, we found that 69% of the pre-
dicted promoter peaks were CpG rich, while only 1.1% of
non-promoter peaks were localized in CpG-rich regions
(Figure 2C). Further, the proportion of CpG rich pro-
moters did not vary signiﬁcantly across the tissues, with
a maximum of 73.8% and a minimum of 67.7% CpG-rich
promoters found in spleen and kidney respectively. Next,
we analyzed the enrichment of Pol-II on the CpG rich and
CpG poor (non CpG) promoters and found higher
binding of Pol-II on CpG rich than non-CpG promoters
in all tissues except spleen where the reverse is observed
(Supplementary Figure S3A in additional data ﬁle 1). In
order to provide genome-wide annotation of active pro-
moters in the mouse genome, we combined the promoter
Figure 2. Identiﬁcation of Pol-II peaks related to promoters. (A) Cumulative distribution of Pol-II peaks around known transcription start site (TSS)
of known genes in ﬁve tissues. The distribution shows that many Pol-II bound peaks are either upstream or downstream of known TSS.
(B) Percentage of signiﬁcant Pol-II peaks predicted as promoter and non-promoter peaks by our program in ﬁve tissues. The graph indicates
that majority of the Pol-II peaks do not correspond to promoters (C) Percentage of CpG-rich promoter and non-promoter peaks in ﬁve tissues.
(D) Distribution of annotated peak promoters relative to known TSS for both protein coding and non-coding genes.
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(additional data ﬁle 3). We merged any two consecutive
promoters into a single promoter region if the distance
between corresponding Pol-II peaks in those promoter
regions was <300bp.
Next, we annotated the identiﬁed promoters using a
non-redundant set of 42924 known protein-coding tran-
scripts and 38159 known non-coding transcripts as
described in ‘Materials and Methods’ section
(Supplementary Table S1A in additional data ﬁle 2). A
schematic representation of the step-wise pipeline that
was followed for promoter annotation is shown in
Supplementary Figure S4 in additional data ﬁle 1. We
identiﬁed 21926, 20301, 15720, 21599 and 11401 pro-
moters that are active in brain, kidney, liver, lung and
spleen, respectively (Table 2). About 8173 (21%) of the
promoters were left unassigned to any gene based on our
annotation strategy. In order to account for the
false-negative predictions of the program (known pro-
moters that were not predicted by the program despite
the presence of signiﬁcantly enriched Pol-II peak), all the
Pol-II signiﬁcantly enriched peaks that were predicted as
non-promoters but overlap with the ﬁrst exons of known
transcripts were added into the ﬁnal promoter annotations
presented in Table 2. Using this strategy we had further
annotated 5356 (2.1%), and 8374 (3.2%) of
Pol-II-enriched peaks to known protein-coding and
non-coding genes, respectively (Supplementary Table S4
in additional data ﬁle 2). Eventually, we have identiﬁed a
total of 38639 promoters and annotated 21739 promoters
to only protein-coding genes (15503), another 7406 pro-
moters to only non-coding genes (5354) and 1321 pro-
moters were assigned to both protein coding and
non-coding genes. The list of all annotated promoters
along with the annotation is provided in additional data
ﬁle 4. Many of these promoters were tissue speciﬁc, while
others were shared between two or more tissues as shown
in the Venn diagram (Supplementary Figure S5 in add-
itional data ﬁle 1). In particular, our analysis has identiﬁed
8727 promoters for Pol-II transcribed non-coding genes
with 856, 184, 31 and nine promoters assigned to
lincRNA, miRNA, snoRNA and snRNA genes, respect-
ively (Table 3). As promoters are localized around TSS,
we analyzed the positioning of the identiﬁed promoters
relative to the known TSS and found that for both
protein coding and non-coding genes, promoters were
mostly upstream of the known TSS (Figure 2D). Next,
we examined the presence of bidirectional promoters
among the identiﬁed promoters. We consider a promoter
as bidirectional if it is shared between two genes which are
in opposite orientation and the promoter region either
overlaps with the ﬁrst exon of the transcripts or is
within  1kb of known TSS as previously described (40).
We identiﬁed 1093, 1029, 989, 1125 and 852 bidirectional
promoters in brain, kidney, liver, lung and spleen, respect-
ively. Interestingly, we found that more than 93% of the
bidirectional promoters were CpG rich (Supplementary
Table S5 in additional data ﬁle 2).
Novel promoter identiﬁcation and experimental validation
One of the major goals of this study was the identiﬁcation
of novel promoters in the mouse genome. We have
identiﬁed a total of 12270 novel promoters, which repre-
sents 32% of all the identiﬁed promoters. This suggests
that a large number of promoters that are active in at
least one of the ﬁve tissues were unknown in any of the
current genome-wide annotations. The tissue-wise distri-
bution of the novel promoters is presented in Table 4. We
observed higher enrichment of Pol-II on the novel pro-
moters than known promoters in spleen, while in brain
and lung the reverse was true. In contrast, in kidney and
liver the binding of Pol-II near TSS was similar for known
and novel promoters (Supplementary Figure S3B in add-
itional data ﬁle 1). Additionally, we found that about 34%
of the novel promoters were CpG rich and these novel
promoter regions show similar level of conservation as
known promoters across 30 vertebrate species
(Supplementary Figure S6 in additional data ﬁle 1).
When we analyzed the novel promoters with the known
Table 2. Summary of identiﬁed promoters across ﬁve tissues
Tissue Known promoters Novel promoters Total
Protein-coding Non-coding Both Protein-coding Non-coding Both Unassigned
Brain 11611 3873 207 6274 152 27 4241 21926
Kidney 11141 3520 217 5729 153 25 3520 20301
Liver 9441 2421 114 3889 104 21 2322 15720
Lung 12020 3259 187 6375 169 37 4033 21599
Spleen 7163 1492 63 2742 70 3 1638 11401
Total number of non-redundant promoters identiﬁed 38639
The breakup of Pol-II bound promoters in each tissue is provided as known and novel promoters and their assignment to either protein coding or/
and non-coding genes is indicated.
Table 3. Summary of identiﬁed promoters assigned to non-coding
RNA class across ﬁve tissues
Tissue lincRNA miRNA snoRNA snRNA Others All
Brain 405 113 21 9 4058 4547
Kidney 419 70 19 8 3729 4186
Liver 315 55 17 9 2701 3048
Lung 460 64 16 8 3489 3974
Spleen 249 32 13 6 1752 2011
Overall 856 184 31 9 7740 8727
This table shows the number of promoters assigned to each category of
non-coding RNA in each tissue.
Nucleic AcidsResearch, 2011, Vol.39,No. 1 195promoters of homologous genes, we found that 671 of
these promoters had corresponding known promoters in
other organisms. Next, we looked for the overlap of novel
promoters from our study with CAGE tag clusters
generated by the FANTOM4 project (41). CAGE tag
clusters are found at the 50 end of transcript as well as in
other regions including the internal exons, introns, 30UTR
and intergenic regions. Because CAGE analysis relies on 50
Cap trapper techniques, thus capturing even
post-transcriptionally re-capped mRNA, it has inherent
deﬁciencies as a sole tool to identify promoters (20). We
have observed that for our promoter peaks, 95–97% are
supported by CAGE clusters and surprisingly even 53–
59% of non-promoter peaks also show the presence of
CAGE clusters (Supplementary Figure S7 and
Supplementary Table S6). When we focused on the
overlap of novel promoters with CAGE clusters, as
expected, we observed a 97% correlation. It is worth
noting that only 1.4% of all CAGE tag based predicted
promoters are actually identiﬁed as active promoter by
our approach in the ﬁve adult tissues (Supplementary
Figure S7A). Additionally, we compared non-redundant
EST sequences with the novel promoters and found that
about 62.4% of the novel promoters overlapped with the
50 ends of the ESTs. Furthermore, using the published
mRNA-seq data from mouse brain and liver, we
detected mRNA-seq reads for 68% and 60% of novel
promoters identiﬁed in brain and liver, respectively
(example shown in Supplementary Figure S8 in additional
data ﬁle 1) (42). Thus, the novel promoters identiﬁed by
our approach of promoter prediction on Pol-II-enriched
ChIP-seq data are supported by other independent experi-
mental methods. To further validate the activity of these
novel promoters, we cloned 10 of the randomly selected
novel promoters (NP1-10) and two non-promoter regions
(Ctrl1, 2) upstream of a promoter-less luciferase gene and
measured promoter activity (Supplementary Table S2 in
additional data ﬁle 2). As shown by the wiggle tracks in
Figure 3A, we have identiﬁed a new promoter in all ﬁve
mouse tissues that lies  16kb upstream of the known
mKIAA1632 gene promoter (NP1). The homologous
region in humans represents the promoter for the human
KIAA1632 gene. Similarly, we have identiﬁed a new
promoter in three of the mouse tissues for GPM6A that
lies  175kb upstream of the known GPM6A gene
promoter in mouse (NP8). The homologous region in
humans represents the promoter for the human GPM6A
gene (Figure 3B). These promoters either represent the
unidentiﬁed promoters for KIAA1632 and GPM6A or
drive the expression of unknown genes. Figure 3C shows
the Pol-II binding in one of the regions that was not pre-
dicted as a promoter in our analysis and is considered as
non-promoter. Using transient transfection experiments,
we introduced these constructs in ﬁve different cell lines
(HEK293, DAOY, A549, HepG2 and NIH3T3) and
measured the expression of luciferase gene which is
controlled by the novel promoters or non-promoter
regions. We observed signiﬁcant luciferase expression
(7-fold for NP5 to 304-fold for NP1) from nine of the
10 selected promoters in at least one of the cell lines
(Figure 3D). We did not observe any promoter activity
for the novel promoter NP7 which was identiﬁed in
spleen tissue and it is possible that this is due to the
absence of the proper cell system in our luciferase assays
or NP7 is a false promoter prediction. Based on our
results, we conclude that non-CpG promoters are
underrepresented in the current promoter inventory and
advances in high-throughput sequencing technology
coupled with bioinformatics analysis can help to identify
these.
Alternative promoter usage in the mouse tissues
It is well established that many mammalian genes have
multiple promoters and that these are differentially used
in different cellular context. In agreement, we found
23060 promoters for 16330 protein-coding and 8727 pro-
moters for 6314 (24%) non-coding genes in the ﬁve mouse
tissues that were analyzed. To identify the genes that use
alternative promoters in these different tissues, we
adopted a two-step procedure. The ﬁrst step involved
identiﬁcation of the promoter(s) with bound Pol-II for
each gene in each tissue individually. In the second step,
we compared the identiﬁed promoter for each gene across
the ﬁve tissues. In case the promoters from two or more
tissues overlap with each other by at least 300bp then they
are considered as the same promoter, otherwise they are
deﬁned as distinct promoters (additional data ﬁle 4).
Examples of alternative promoter genes identiﬁed by
Table 4. Novel promoters and relationship with existing information
Tissue Number
of novel
promoters
Percentage
of CpG-rich
promoters
Number of promoters
Homologous to
other organisms
(overlap with 50ends
of XenoRef mRNAs)
Supported by
CAGE cluster
Found in
Bing Ren’s
study (17)
Overlap with
50 of ESTs
Brain 6649 41.21 405 6479 184 4320
Kidney 5857 42.38 372 5722 177 3728
Liver 3972 36.61 250 3887 131 2670
Lung 6507 42.98 392 6318 208 4015
Spleen 2809 42.11 160 2724 95 1775
Overall 12270 33.85 671 11902 371 7663
This table shows the support of the identiﬁed novel promoters from other experimental sources in every tissue.
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Figure 4A. In case of Adar1, there are two active pro-
moters that are differentially used in the ﬁve tissues. The
upstream promoter P1 is used in brain, kidney and lung,
while downstream P2 promoter has been identiﬁed as
active in kidney, liver, lung and spleen. Similarly for
Hdgf, four distinct active promoters have been identiﬁed
that are differentially enriched with Pol-II. Based on this
analysis, we have found the distribution of multi-promoter
usage in ﬁve mouse tissues (Figure 4B and C). We
observed that 37% of the annotated protein-coding
genes and 31% of the non-coding genes use alternative
promoters in the ﬁve mouse tissues. Furthermore, we
found that the use of alternative promoters changes the
coding protein in 34.5% of the alternative promoter genes.
As our analysis is based on only ﬁve tissues, it suggests
that a signiﬁcant number of mouse genes use alternative
promoters.
Identiﬁcation of tissue-speciﬁc promoters
Having identiﬁed the promoters that are active in one or
more of the ﬁve tissues, we further investigated the usage
of promoters in a tissue-speciﬁc manner. Two different
parameters were used for identifying tissue-speciﬁc pro-
moters in our study. The ﬁrst parameter is based on
Shannon entropy that was previously employed for iden-
tifying tissue-speciﬁc promoters from ChIP–chip (17),
gene expression and EST data (43). As the second param-
eter, we deﬁne fold change for each promoter (p) as
fp=max1/max2, where max1 and max2 are the ﬁrst and
second highest normalized read counts for promoter p
Figure 3. Identiﬁcation of novel promoters and experimental veriﬁcation. (A–C) The wiggle proﬁle shows the enrichment of Pol-II and prediction of
novel promoters for mouse KIAA1632 (A) and GPM6 (B) gene in brain, kidney, liver, lung, and spleen tissues and (C) shows the Pol-II proﬁle on a
non-promoter region that lies within the transcripts (AK090117 and U58494). Y-axis shows the normalized read counts/million mapped reads and
the black boxes below the Pol-II-binding proﬁle represent the identiﬁed novel promoters by our program. The two novel promoters shown above
have a corresponding conserved promoter in human genome. (D) Luciferase activity of the novel promoters in ﬁve distinct cell lines. The x-axis
represents either the vector alone background (pGL3 basic) or the activity of novel promoters (NP1-10) and non-promoter region (ctrl1 and 2).
On the y-axis, the normalized luciferase activity has been plotted in a logarithmic scale to the base of 2. Thus, the value of 1on the y-axis represents a
2-fold activity of the promoter. Only if a promoter shows an activity that is more than 2-fold it is considered as active in that cell line. NP7 does not
show any luciferase activity in any of the ﬁve cell lines. Luciferase activity is expressed as log2 of the fold change over the vector alone (pGL3basic)
after normalization with Renilla-luciferase for transfection efﬁciency. Dll1 promoter has been included as a positive control and Ctrl1, 2 represents
the negative controls (non-promoter regions).
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ciﬁcity, we have set the maximum cutoff as 1.25 for
Shannon entropy and a minimum cutoff of 2.0 for the
fold change determinant. Note that while Shannon
entropy is inversely correlated, the fold-change parameter
is directly correlated with tissue speciﬁcity. Using the
above-deﬁned parameters, we have identiﬁed 6384
tissue-speciﬁc promoters across the ﬁve mouse tissues
(Supplementary Table S7 in additional data ﬁle 2 and
additional data ﬁle 5). These results are further supported
by the box plot, which shows as an example for the
brain-speciﬁc promoters a signiﬁcantly higher read count
in brain compared to the other four tissues in the distri-
bution of normalized read counts (Figure 5A). Similar
results were obtained for other tissue-speciﬁc promoters
(Supplementary Figure S9 in additional data ﬁle 1). The
highest number of tissue-speciﬁc promoters was identiﬁed
in brain while spleen has the least number of tissue-speciﬁc
Pol-II-associated promoters. Further analysis revealed
that overall only 29% of the tissue-speciﬁc promoters
were CpG rich, with brain and lung exhibiting highest
CpG richness ( 41%), while in spleen only 9% of pro-
moters were CpG rich. We further studied the relationship
of tissue-speciﬁc parameters: Shannon entropy and
normalized read fold change with CpG richness in pro-
moters of genes (Figure 5B and C). A direct relationship is
observed between CpG richness and Shannon entropy and
an inverse relationship is observed between CpG richness
and normalized read fold-change for promoters, suggest-
ing that globally the tissue-speciﬁc promoters are CpG
poor compared to ubiquitous promoters. Furthermore,
detailed analysis of core promoter elements in the
tissue-speciﬁc promoters versus ubiquitous promoters
show that TATA (p=1.75e-14) and INR (p=1.69e-12)
elements are more enriched in tissue-speciﬁc promoters,
while BRE (p=4.56e-29) and MTE (p=6.82e-18)
elements are signiﬁcantly enriched in ubiquitous genes
(Supplementary Table S8A and B in additional data ﬁle
2, statistical signiﬁcance was calculated using proportion
test). DPE element did not show any preference for either
class of promoters. Thus, our data suggests hat CpG-poor
tissue-speciﬁc promoters and CpG-rich ubiquitous pro-
moters tend to possess different core promoter compos-
ition (44).
Correlation of Pol-II binding at promoter and the
corresponding transcript expression
As binding of Pol-II precedes transcription, we expected
that promoters with high occupancy of Pol-II will be
transcribed at a higher rate than others. To address this
issue, we studied the correlation of Pol-II recruitment to
the promoter and the consequential transcript expression
in the mouse tissues. We performed this analysis for only
Figure 4. Alternative promoter usage in ﬁve mouse tissues (A) Wiggle proﬁle showing examples of alternative promoter usage identiﬁed by our
analysis in the ﬁve mouse tissues. For Adar1 and Hdgf our approach has identiﬁed the use of two and four known promoters among the ﬁve tissues,
which are indicated by arrows on the transcripts at the bottom of the ﬁgure. Y-axis shows the normalized read count per million reads, the black box
below the Pol-II enrichment shows the position of the identiﬁed promoters and the black line under it indicates the signiﬁcantly enriched peaks of
each track. It is evident that only few of the enriched peaks reside in the promoter region. (B and C) Pie chart shows distribution of alternative
promoter usage for protein coding (B) and non-coding genes (C) in the ﬁve tissues analyzed from mouse.
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data (42). We used Cufﬂinks software (45) to estimate
the transcript expression from the mRNA-seq data sets
using the default parameters. For each tissue, the expres-
sion scores from promoters were broken up into four
quartiles: high, medium, low and very low. Next, we
calculated the average Pol-II ChIP-seq read count
around annotated TSS at base pair resolution for pro-
moters found in the four quartiles and plotted the
Pol-II-enriched proﬁle around annotated TSS (Figure 6).
Because there is no mRNA-seq data available for kidney,
lung and spleen, we performed similar analysis at the
gene level using microarray gene expression data
(Supplementary Figure S10). The gene expression data
used in our present study for brain, kidney, liver, lung
and spleen were downloaded from NCBI (GEO ID:
GDS592) (46). As these data contained proﬁles for eight
different brain tissues, (frontal cortex, cerebral cortex,
substantia nigra, cerebellum, amygdala, hypothalamus,
hippocampus and dorsal striatum), the average of these
scores for each gene was taken as the expression of the
corresponding gene in brain. Altogether, we observe that
the promoters driving higher mRNA expression exhibit
increased Pol-II recruitment, suggesting that the binding
of Pol-II at the promoter is a good signature for global
expression from a promoter.
DISCUSSION
Identiﬁcation and annotation of all human and mouse
gene promoters that are differentially used in different
cell/tissue types, during development, or aberrantly
activated in disease conditions are still incomplete and
are essential for deﬁning the transcriptome and
proteome of the mammalian genome. It is well known
that differential gene expression is a characteristic of dif-
ferent tissues; however, not much work has been done to
characterize the global isoform speciﬁc expression of genes
in various tissues (47,48). One of the important aspects to
understand the regulation of gene expression is the study
of all the promoters of a gene. Currently, our promoter
knowledge is partial and our goal in this study was to
expand our promoter inventory and to determine the
tissues where each promoter is active. To provide a
catalog of active promoters in various tissues and
identify tissue-speciﬁc promoter usage, we used a combin-
ation of ChIP-seq and bioinformatics approaches. In this
study, we focused on ﬁve adult tissues—brain, kidney,
liver, lung and spleen, and have successfully identiﬁed
38639 promoters for both protein coding and non-coding
genes. Our approach has identiﬁed 12270 novel promoters
including promoters for genes such as Dnmt1, Bmp4,
Jmjd3, Cyclin E1 and D1, MeCP2, which have been
associated with tumorigenesis. We have been able to
annotate a large number of the newly discovered pro-
moters to known genes like 60% in case of brain, and
we anticipate that the remaining 40% un-annotated pro-
moters might mostly represent the promoters of unknown
non-coding genes. Our results also show that about 37%
of the protein coding genes possess alternative promoters.
This is lower than the expected 50–60% genes from other
genome-wide analysis due to the small number of tissues
assayed as well as the sole use of adult tissue in this study
(11,44). This is supported by our analysis where we
compared the alternative promoter use in two, three,
four, ﬁve tissues and observed an increase in alternative
promoter usage from 27% (two-tissue) to 37%
(ﬁve-tissue). The use of alternative promoters results in
different proteins in about 34% of multi-promoter genes
as seen for Adar1, Hdgf (Figure 4A). In case of Adar1, the
upstream promoter P1 is responsive to interferon and
produces a 150-kDa protein compared to the constitutive
promoter P2 that produces an N-terminally truncated
110-kDa protein (49). We have found that 5–8% of the
Figure 5. Identiﬁcation of tissue speciﬁc promoters and their relation-
ship to CpG islands. (A) Box plot shows the normalized read counts of
promoters that have been assigned to be brain speciﬁc in all ﬁve mouse
tissues. The plot shows that the brain speciﬁc promoters indeed show
speciﬁc and increased Pol-II binding in brain relative to other tissues.
(B and C) Tissue speciﬁcity of promoters and its association with CpG
richness. An inverse relationship is observed between tissue-speciﬁc pro-
moters and CpG richness when we look at either the Shannon entropy
(B) or normalized read count fold change (C) measures of tissue spe-
ciﬁcity across all ﬁve tissues. The left-hand side of y-axis represents the
total promoter count. The right side of y-axis represents fraction of
CpG-rich promoters. The x-axis in (B) represents Shannon entropy
and in (C) it represents log2 (fold change) in read count value
around annotated promoters.
Nucleic AcidsResearch, 2011, Vol.39,No. 1 199promoters in these tissues are bidirectional and 4–6% of
the promoters are shared by protein coding and
non-coding genes in each tissue. Our analysis suggests
that nearly 17% of the promoters in the mouse genome
are used in a tissue-speciﬁc manner and these tissue re-
strictive promoters tend to be CpG poor. We found that
almost 70% of the known promoters are CpG rich, while
66% of the novel promoters are CpG poor suggesting that
many of these new promoters are tissue-speciﬁc and not
easily identiﬁable without high-throughput genome-wide
analysis. This is supported by the ﬁnding that, while 1/4th
of the highly tissue restrictive (active in only one tissue)
novel promoters are CpG rich, 2/3rd of the novel pro-
moters active in the ﬁve tissues show CpG richness. In
conclusion, we have identiﬁed the active promoters in
ﬁve mouse tissues and we plan to expand our study to
identify the differential and overlapping use of promoters
in normal human tissues and diseased tissue counterparts.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online. ChIP-
seq data has been deposited in GEO under accession
number GSE 21773.
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